395 related articles for article (PubMed ID: 32722245)
1. Does Siponimod Exert Direct Effects in the Central Nervous System?
Kipp M
Cells; 2020 Jul; 9(8):. PubMed ID: 32722245
[TBL] [Abstract][Full Text] [Related]
2. Siponimod (BAF312) Activates Nrf2 While Hampering NFκB in Human Astrocytes, and Protects From Astrocyte-Induced Neurodegeneration.
Colombo E; Bassani C; De Angelis A; Ruffini F; Ottoboni L; Comi G; Martino G; Farina C
Front Immunol; 2020; 11():635. PubMed ID: 32322257
[TBL] [Abstract][Full Text] [Related]
3. Siponimod in the treatment of multiple sclerosis.
Goodman AD; Anadani N; Gerwitz L
Expert Opin Investig Drugs; 2019 Dec; 28(12):1051-1057. PubMed ID: 31603362
[No Abstract] [Full Text] [Related]
4. Siponimod and CYP2C9 Allele Prevalence Among Blacks.
Liu M; Obeng AO
J Clin Pharmacol; 2020 Apr; 60(4):429-431. PubMed ID: 31701536
[No Abstract] [Full Text] [Related]
5. Siponimod to treat secondary progressive multiple sclerosis.
Gajofatto A; Turatti M
Drugs Today (Barc); 2020 Jan; 56(1):37-46. PubMed ID: 32055804
[TBL] [Abstract][Full Text] [Related]
6. Siponimod: First Global Approval.
Al-Salama ZT
Drugs; 2019 Jun; 79(9):1009-1015. PubMed ID: 31144287
[TBL] [Abstract][Full Text] [Related]
7. Siponimod for the treatment of secondary progressive multiple sclerosis.
Dumitrescu L; Constantinescu CS; Tanasescu R
Expert Opin Pharmacother; 2019 Feb; 20(2):143-150. PubMed ID: 30517042
[TBL] [Abstract][Full Text] [Related]
8. Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date.
Gajofatto A
Drug Des Devel Ther; 2017; 11():3153-3157. PubMed ID: 29138536
[TBL] [Abstract][Full Text] [Related]
9. Siponimod ameliorates metabolic oligodendrocyte injury via the sphingosine-1 phosphate receptor 5.
Behrangi N; Heinig L; Frintrop L; Santrau E; Kurth J; Krause B; Atanasova D; Clarner T; Fragoulis A; Joksch M; Rudolf H; Meuth SG; Joost S; Kipp M
Proc Natl Acad Sci U S A; 2022 Oct; 119(40):e2204509119. PubMed ID: 36161894
[TBL] [Abstract][Full Text] [Related]
10. Siponimod Attenuates Neuronal Cell Death Triggered by Neuroinflammation via NFκB and Mitochondrial Pathways.
Gurrea-Rubio M; Wang Q; Mills EA; Wu Q; Pitt D; Tsou PS; Fox DA; Mao-Draayer Y
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473703
[TBL] [Abstract][Full Text] [Related]
11. Impact of Siponimod on Enteric and Central Nervous System Pathology in Late-Stage Experimental Autoimmune Encephalomyelitis.
Weier A; Enders M; Kirchner P; Ekici A; Bigaud M; Kapitza C; Wörl J; Kuerten S
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430692
[TBL] [Abstract][Full Text] [Related]
12. The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis.
Cohan SL; Benedict RHB; Cree BAC; DeLuca J; Hua LH; Chun J
CNS Drugs; 2022 Jul; 36(7):703-719. PubMed ID: 35725892
[TBL] [Abstract][Full Text] [Related]
13. Siponimod Modulates the Reaction of Microglial Cells to Pro-Inflammatory Stimulation.
Gruchot J; Lein F; Lewen I; Reiche L; Weyers V; Petzsch P; Göttle P; Köhrer K; Hartung HP; Küry P; Kremer D
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362063
[TBL] [Abstract][Full Text] [Related]
14. Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis.
Gentile A; Musella A; Bullitta S; Fresegna D; De Vito F; Fantozzi R; Piras E; Gargano F; Borsellino G; Battistini L; Schubart A; Mandolesi G; Centonze D
J Neuroinflammation; 2016 Aug; 13(1):207. PubMed ID: 27566665
[TBL] [Abstract][Full Text] [Related]
15. Siponimod (BAF312) Treatment Reduces Brain Infiltration but Not Lesion Volume in Middle-Aged Mice in Experimental Stroke.
Vogelgesang A; Domanska G; Ruhnau J; Dressel A; Kirsch M; Schulze J
Stroke; 2019 May; 50(5):1224-1231. PubMed ID: 31009359
[TBL] [Abstract][Full Text] [Related]
16. Siponimod Inhibits the Formation of Meningeal Ectopic Lymphoid Tissue in Experimental Autoimmune Encephalomyelitis.
Brand RM; Diddens J; Friedrich V; Pfaller M; Radbruch H; Hemmer B; Steiger K; Lehmann-Horn K
Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34911793
[TBL] [Abstract][Full Text] [Related]
17. Anti-inflammatory effects of siponimod on astrocytes.
Ogasawara A; Takeuchi H; Komiya H; Ogawa Y; Nishimura K; Kubota S; Hashiguchi S; Takahashi K; Kunii M; Tanaka K; Tada M; Doi H; Tanaka F
Neurosci Res; 2022 Nov; 184():38-46. PubMed ID: 35940437
[TBL] [Abstract][Full Text] [Related]
18. Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis.
Roy R; Alotaibi AA; Freedman MS
CNS Drugs; 2021 Apr; 35(4):385-402. PubMed ID: 33797705
[TBL] [Abstract][Full Text] [Related]
19. Substantial disease exacerbation in a patient with relapsing-remitting multiple sclerosis after withdrawal from siponimod.
Litwin T; Smoliński Ł; Członkowka A
Neurol Neurochir Pol; 2018; 52(1):98-101. PubMed ID: 29110882
[TBL] [Abstract][Full Text] [Related]
20. Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis.
Chaudhry BZ; Cohen JA; Conway DS
Neurotherapeutics; 2017 Oct; 14(4):859-873. PubMed ID: 28812220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
